Dr. Mark N. Stein
Claim this profileColumbia University Irving Medical Center
Area of expertise
Prostate Cancer
Mark N. Stein has run 12 trials for Prostate Cancer. Some of their research focus areas include:
Cancer
Mark N. Stein has run 6 trials for Cancer. Some of their research focus areas include:
Affiliated Hospitals
Columbia University Irving Medical Center
Columbia University Medical Center
Clinical Trials Mark N. Stein is currently running
Surgery + Immunotherapy + Targeted Therapy
for Kidney Cancer
The purpose of this study is to determine if the use of immunotherapy nivolumab and the targeted therapy cabozantinib prior to removal of the kidney, will increase the number subjects who are without any visible kidney cancer in their body at some point during the course of treatment.
Recruiting
1 award
Phase 2
10 criteria
Registry
for Advanced Prostate Cancer
Our intent is to establish the International Registry to Improve Outcomes in Men with Advanced Prostate Cancer (IRONMAN) as a prospective, international cohort of minimum 5,000 men with advanced cancer, including men with mHSPC and M0/M1 CRPC. The goal is to establish a population-based registry and recruit patients across academic and community practices from Australia, Barbados, Brazil, Canada, Ireland, Jamaica, Kenya, Nigeria, Norway, Spain, South Africa, Sweden, Switzerland, the United Kingdom (UK), and the United States (US). Target accrual number and number of participating sites are subject to change based on accrual, funding, and interest in participation by other international sites. This cohort study will facilitate a better understanding of the variation in care and treatment of advanced prostate cancer across countries and across academia and community based practices. Detailed data will be collected from patients at study enrollment and then during follow-up, for a minimum of five years. Patients will be followed prospectively for overall survival, clinically significant adverse events, comorbidities, changes in cancer treatments, and PROMs. PROMs questionnaires will be collected at enrollment and every three months thereafter. Physician Questionnaires will be collected from all participating sites at patient enrollment, time of first change in treatment and/or one year follow-up, at each subsequent change of treatment, and discontinuation of treatment. As such, this registry will help identify the treatment sequences or combinations that optimize overall survival and PROMs for men with mHSPC and M0/M1 CRPC. By collecting blood at enrollment, time of first change in treatment and/or one year follow-up (plasma, cell free DNA, buffy coat / RNA), this registry will further identify and validate molecular phenotypes of disease that predict response and resistance to specific therapeutics. Additionally, every effort will be made to collect blood specimen at each subsequent change in treatment due to progression of disease. When feasible, existing tumor tissue may be collected for correlation with described blood based studies. All samples will be used for future research. This cohort study will provide the research community with a unique biorepository to identify biomarkers of treatment response and resistance.
Recruiting
1 award
N/A
5 criteria
More about Mark N. Stein
Clinical Trial Related
3 years of experience running clinical trials · Led 18 trials as a Principal Investigator · 4 Active Clinical Trials
Treatments Mark N. Stein has experience with
- Nivolumab
- Cabozantinib
- Degarelix
- Docetaxel
- Leuprolide Acetate
- REGN2810
Breakdown of trials Mark N. Stein has run
Prostate Cancer
Cancer
Lung Cancer
Renal Cell Carcinoma
Other Doctors you might be interested in
Frequently asked questions
Do I need insurance to participate in a trial?
Almost all clinical trials will cover the cost of the ‘trial drug’ — so no insurance is required for this. For trials where this trial drug is given alongside an already-approved medication, there may be a cost (which your insurance would normally cover).
What does Mark N. Stein specialize in?
Mark N. Stein focuses on Prostate Cancer and Cancer. In particular, much of their work with Prostate Cancer has involved Stage IV patients, or patients who are MET positive.
Is Mark N. Stein currently recruiting for clinical trials?
Yes, Mark N. Stein is currently recruiting for 4 clinical trials in New York New York. If you're interested in participating, you should apply.
Are there any treatments that Mark N. Stein has studied deeply?
Yes, Mark N. Stein has studied treatments such as Nivolumab, Cabozantinib, Degarelix.
What is the best way to schedule an appointment with Mark N. Stein?
Apply for one of the trials that Mark N. Stein is conducting.
What is the office address of Mark N. Stein?
The office of Mark N. Stein is located at: Columbia University Irving Medical Center, New York, New York 10032 United States. This is the address for their practice at the Columbia University Irving Medical Center.
Is there any support for travel costs?
The coverage of travel expenses can vary greatly between different clinical trials. Please see more financial detail in the trials you’re interested to apply.
Unbiased Results
We believe in providing patients with all the options.
Your Data Stays Your Data
We only share your information with the clinical trials you're trying to access.
Verified Trials Only
All of our trials are run by licensed doctors, researchers, and healthcare companies.